{"key":"op_491_IT","page":{"url":"https://us-uk.bookimed.com/clinics/country=italy/procedure=keytruda/","procedure":{"id":491,"slug":"keytruda","name":"Immunotherapy with Keytruda (Pembolizumab)","name_forms":{"plural":{"status":"missing","reason":"not_collected"},"genitive":{"status":"missing","reason":"not_collected"}},"type":"therapy","grammar_number":{"status":"missing","reason":"not_collected"},"parent_id":"oncology","family_attribute":{"status":"missing","reason":"not_collected"}},"country":{"id":127,"iso":"IT","name":"Italy"},"currency":"USD","data_date":"2026-11-11"},"pages":{"clinics_url":"https://us-uk.bookimed.com/clinics/country=italy/procedure=keytruda/","cost_url":"https://us-uk.bookimed.com/clinics/country=italy/procedure=keytruda/cost/","best_url":{"status":"missing","reason":"template not live"}},"price":{"from":4300,"to":6700,"avg":{"status":"missing","reason":"no_offers"},"us":{"from":13500,"to":22000},"uk":{"from":7000,"to":10500},"by_technique":[{"technique":"Pembrolizumab monotherapy","technique_id":"pembrolizumab-monotherapy","price_from":4300,"currency":"USD","source":"estimate","date":"2026-11-17"},{"technique":"Pembrolizumab combined with chemotherapy","technique_id":"pembrolizumab-combined","price_from":5300,"currency":"USD","source":"estimate","date":"2026-11-17"}],"by_city":[{"city":"Milan","from":4300}],"per_unit":{"status":"missing","reason":"not_collected"},"factors":{"status":"missing","reason":"not_collected"},"tiers":{"status":"missing","reason":"no_offers"},"comparison":[{"country_iso":"UA","from":4500,"to":8000},{"country_iso":"FR","from":4200,"to":7000},{"country_iso":"GB","from":7000,"to":10500},{"country_iso":"US","from":13500,"to":22000},{"country_iso":"IL","from":4800,"to":6800},{"country_iso":"TR","from":2800,"to":7000},{"country_iso":"MX","from":3800,"to":5500},{"country_iso":"DE","from":6000,"to":8100},{"country_iso":"CA","from":6800,"to":9800},{"country_iso":"AE","from":5600,"to":8600},{"country_iso":"TH","from":3600,"to":4600},{"country_iso":"PL","from":4300,"to":5800},{"country_iso":"KR","from":4800,"to":7500},{"country_iso":"CZ","from":3600,"to":5300},{"country_iso":"AT","from":5800,"to":8400},{"country_iso":"ES","from":13500,"to":{"status":"missing","reason":"not_collected"}},{"country_iso":"CN","from":4500,"to":7200},{"country_iso":"AU","from":4800,"to":7400},{"country_iso":"IN","from":2500,"to":5200},{"country_iso":"MY","from":3800,"to":5400},{"country_iso":"VN","from":4300,"to":6200},{"country_iso":"BR","from":4500,"to":7000},{"country_iso":"EG","from":1500,"to":6300}],"base_country":"US","base_is_fallback":false},"savings":{"pct":68,"variant":">=15%"},"package":{"included":{"status":"missing","reason":"no_offers"},"excluded":{"status":"missing","reason":"no_offers"},"extra_charges":{"status":"missing","reason":"not_collected"}},"clinics":{"count":1,"items":[{"id":303,"name":"San Raffaele","city":"Milan","rating":4.6,"reviews_count":71,"accreditations":["Scientific Institute for Research and Healthcare Accrediatation","World's Best Hospitals 2021 by Newsweek"],"rank":1,"has_procedure":true,"why_ranked":"Specializes in oncology with a multidisciplinary team. Clinic performs 52,000 operations annually and offers tailored immunotherapy programs. 4.5-star rating based on patient reviews.","bookimed_stats":{"status":"missing","reason":"not_published"},"procedure_description":{"status":"missing","reason":"not_collected"},"offers":{"status":"missing","reason":"no_offers"}}]},"doctors":{"count":{"status":"missing","reason":"not_collected"},"languages":{"status":"missing","reason":"not_collected"}},"cities":[{"id":353,"slug":"milan","name":"Milan","clinics_count":{"status":"missing","reason":"not_collected"},"price_from":4300,"profile":{"city_type":"Capital and largest city of Lombardy","access":["Malpensa Airport (MXP), 49 km from Milan","Linate Airport (LIN), 7 km from the city center"],"sources":["https://en.wikipedia.org/wiki/Milan","https://en.wikipedia.org/wiki/Milan_Malpensa_Airport","https://en.wikipedia.org/wiki/Linate_Airport"],"checked_at":"2026-11-03","status":"ok"}}],"offers":{"active":{"status":"missing","reason":"no_offers"},"active_with_related":{"status":"missing","reason":"no_offers"},"hospital_nights_median":{"status":"missing","reason":"no_offers"},"days_in_country_median":{"status":"missing","reason":"no_offers"},"top_offers":{"status":"missing","reason":"no_offers"},"packages":{"status":"missing","reason":"no_offers"},"related_packages":{"status":"missing","reason":"no_offers"},"other_packages":{"status":"missing","reason":"no_offers"}},"medical":{"indications":["Advanced or metastatic melanoma; adjuvant melanoma after resection","Non-small cell lung cancer (alone or with chemotherapy)","Head and neck squamous cell carcinoma","Classical Hodgkin lymphoma (relapsed/refractory)","Urothelial carcinoma","MSI-high/dMMR solid tumors including colorectal cancer","Other approved cancers (cervical, endometrial, gastric, renal, breast)","Merkel cell carcinoma"],"contraindications":["Prior severe hypersensitivity to pembrolizumab or its components","Pregnancy (can harm the fetus)","Severe active autoimmune disease needing immunosuppression (relative)","Active uncontrolled infection (relative; treat first)","Prior solid organ transplant (relative; graft rejection risk)"],"operation_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Dose (200 mg every 3 weeks or 400 mg every 6 weeks) infused over 30 minutes, plus brief observation."},"anesthesia":["none"],"sessions_or_stages":{"sessions":{"min":1,"max":35,"unit":"visits","qualifier":"Infusions every 3 or 6 weeks for up to about 2 years (35 three-weekly cycles) or until progression."},"stages":[{"code":"infusion_cycles","label":"Repeated intravenous pembrolizumab infusions every 3 or 6 weeks","after":{"min":0,"max":730,"unit":"days","qualifier":"Spans the whole course from the first infusion."}}],"qualifier":"Number of cycles depends on cancer type, regimen, response and tolerance."},"hospital_nights":{"value":{"min":0,"max":0,"unit":"nights","qualifier":"Per infusion; given as an outpatient infusion with no overnight stay."},"source":"parsed_details"},"treatment_conditions":["outpatient"],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Outpatient infusion with no surgical recovery; usual activities resume within 0-2 days, depending on fatigue and side effects."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Outpatient infusion with no wound; flying is possible once no reaction occurs and you feel well."},"back_to_work_days":{"min":0,"max":2,"unit":"days","qualifier":"Most return to usual activities within 0-2 days, depending on fatigue, side effects and cancer type."},"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"No procedural restriction; light activity encouraged. Strenuous exercise within about a week, limited by fatigue."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Best response often seen within 3-6 months; responses may deepen later."},"result_longevity":"In responders, benefit is often durable, lasting years and sometimes continuing after the course (up to about 2 years) ends. Duration depends on cancer type, stage and biomarkers.","main_risks":["Immune-related organ inflammation (lungs, colon, liver, thyroid, kidneys, skin)","Fatigue, rash, itching, diarrhea, nausea","Infusion-related reactions","Type 1 diabetes, adrenal or pituitary insufficiency","Myocarditis (rare)","Serious or fatal immune events needing steroids and interruption"],"complication_rate_pct":{"min":10,"max":20,"unit":"percent","qualifier":"Grade 3-5 treatment-related adverse events with monotherapy in pivotal trials; higher with chemotherapy or TKIs."},"revision_rate_pct":{"status":"missing","reason":"not_collected"},"success":{"metric":"Overall survival at 5 years (advanced NSCLC, PD-L1 ≥50%)","value":31.9,"horizon":"5 years","source":{"status":"missing","reason":"not_collected"},"evidence_status":"limited"},"scars":"No scarring is expected; at most there is a tiny, temporary mark at the IV cannulation site.","pain":"Minimal; only mild discomfort from IV cannulation. Side effects such as joint or muscle pain may occur in some patients.","preparation":["Confirmed cancer and approved indication; biomarker testing if relevant","Baseline blood tests: liver, kidney, thyroid, glucose","Baseline imaging for staging","Review of autoimmune history, transplant history and current medications","Pregnancy test and contraception counseling where relevant","Discussion of side effects and when to report symptoms urgently","Hepatitis B/C and HIV screening; exclude active tuberculosis","Baseline ECOG performance status assessment","Adequate venous access for intravenous infusion"],"recovery_timeline":[{"phase":"Infusion day","description":"About 30-minute IV infusion with brief observation; most patients go home the same day.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"First days after each infusion","description":"Possible mild fatigue, rash or flu-like symptoms. Promptly report cough, breathlessness, severe diarrhea or rash, jaundice or weakness.","restrictions":{"status":"missing","reason":"not_collected"}},{"phase":"Ongoing treatment","description":"Cycles every 3 or 6 weeks with monitoring for delayed immune-related side effects, which can appear months into treatment or after it ends.","restrictions":["Do not self-treat immune-related symptoms; contact the oncology team"]}],"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Clinical review and blood tests before each subsequent cycle (every 3 or 6 weeks depending on regimen)."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"First response imaging is typically about 6-12 weeks after starting treatment."}}],"sources":{"status":"missing","reason":"not_collected"},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the medical team treating you has suitable qualifications","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check that you can ask the treating team questions about your treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Check that you are satisfied with the facilities and standards where you will be treated","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Are you satisfied with the facilities and standards at the clinic or hospital where you'll be treated?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check how your aftercare will be coordinated once treatment is over","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C5","text":"Check whether follow-up care takes place at the same facility as the procedure","scope":"treatment_abroad","source":{"url":"https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html","host":"cdc.gov","quote":"Medical tourists should also know whether follow-up care is scheduled to occur at the same facility as the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"The clinic or hospital refuses to discuss the details of the treatment when asked","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Be wary of surgeons and hospitals that do not want to discuss the details of surgery with you.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Fevers or flu-like symptoms with a rash","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Contact your care team right away if you notice fevers or flu-like symptoms with a rash.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Allergic reaction to the medicine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.healthline.com/health/drugs/keytruda","host":"healthline.com","quote":"Call your doctor right away if you have an allergic reaction to Keytruda.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Any change in eyesight","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Tell your care team right away if you have any change in your eyesight.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Shortness of breath or trouble breathing","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Dry cough, shortness of breath or trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W5","text":"Chest pain or fast or irregular heartbeat","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Heart muscle inflammation—unusual weakness or fatigue, shortness of breath, chest pain, fast or irregular heartbeat.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Gives your home doctor information about your treatment and future care needs","document":"discharge letter for gp","source":{"url":"https://www.nhs.uk/using-the-nhs/nhs-services/hospitals/being-discharged-from-hospital/","host":"nhs.uk","quote":"You'll also be given a letter for your GP, providing information about your treatment and future care needs.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T4","text":"Tells any doctor the patient is on immunotherapy, so side effects are managed correctly","document":"immunotherapy wallet card","source":{"url":"https://www.ons.org/toolkits/immunotherapy-patient-wallet-card-1","host":"ons.org","quote":"The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Liver function test","aliases":["Liver function test","liver","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney","kidney function","renal function"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Thyroid function test","aliases":["Thyroid function test","thyroid","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Blood glucose test","aliases":["Blood glucose test","glucose","blood glucose"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Pregnancy test","aliases":["Pregnancy test"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test and contraception counseling where relevant"}],"what_it_checks":{"text":"Checks whether pregnancy is present because treatment can cause fetal harm","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis B test","aliases":["Hepatitis B test","Hepatitis B/C screening","hepatitis B screening","HBV","Hepatitis C test","hepatitis C screening","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"HIV test","aliases":["HIV test","HIV screening","HIV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1","PD-L1 test results"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Shows PD-L1 protein in tumor cells, guiding immunotherapy choice","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called programmed-death ligand 1 (PD-L1) is found on the cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"type":"case","text":"If you have certain types of cancer","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need a PD-L1 test if you've been diagnosed with certain types of cancer that commonly cause high PD-L1 levels.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"test_prep":{"text":"Preparation varies with how the tumor sample is collected","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Preparations for your test depend on how your tissue sample will be taken.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}},{"id":"T10","name":"MSI test","aliases":["MSI test","MSI","microsatellite instability"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Checks tumor MSI-high status, which decides if Keytruda can treat it","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":2},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}},"parsed_details":{"procedure_type":"therapy","fields":{"anesthesia":["none"],"back_to_work_days":{"min":0,"max":2,"unit":"days","qualifier":"Most return to usual activities within 0-2 days, depending on fatigue, side effects and cancer type."},"complication_rate_pct":{"min":10,"max":20,"unit":"percent","qualifier":"Grade 3-5 treatment-related adverse events with monotherapy in pivotal trials; higher with chemotherapy or TKIs."},"contraindications":["Prior severe hypersensitivity to pembrolizumab or its components","Pregnancy (can harm the fetus)","Severe active autoimmune disease needing immunosuppression (relative)","Active uncontrolled infection (relative; treat first)","Prior solid organ transplant (relative; graft rejection risk)"],"days_in_clinic":{"min":0,"max":0,"unit":"nights","qualifier":"Per infusion; given as an outpatient infusion with no overnight stay."},"diagnostic_duration_minutes":null,"diagnostic_preparation":null,"diagnostic_referral_needed":null,"diagnostic_result_time_hours":null,"exercise_resume_weeks":{"min":0,"max":1,"unit":"weeks","qualifier":"No procedural restriction; light activity encouraged. Strenuous exercise within about a week, limited by fatigue."},"final_result_months":{"min":3,"max":6,"unit":"months","qualifier":"Best response often seen within 3-6 months; responses may deepen later."},"fly_home_after_days":{"min":1,"max":2,"unit":"days","qualifier":"Outpatient infusion with no wound; flying is possible once no reaction occurs and you feel well."},"follow_up_visits":[{"purpose":"assessment","requirement":"routine","after":{"min":21,"max":42,"unit":"days","qualifier":"Clinical review and blood tests before each subsequent cycle (every 3 or 6 weeks depending on regimen)."}},{"purpose":"result_review","requirement":"routine","after":{"min":42,"max":84,"unit":"days","qualifier":"First response imaging is typically about 6-12 weeks after starting treatment."}}],"indications":["Advanced or metastatic melanoma; adjuvant melanoma after resection","Non-small cell lung cancer (alone or with chemotherapy)","Head and neck squamous cell carcinoma","Classical Hodgkin lymphoma (relapsed/refractory)","Urothelial carcinoma","MSI-high/dMMR solid tumors including colorectal cancer","Other approved cancers (cervical, endometrial, gastric, renal, breast)","Merkel cell carcinoma"],"main_risks":["Immune-related organ inflammation (lungs, colon, liver, thyroid, kidneys, skin)","Fatigue, rash, itching, diarrhea, nausea","Infusion-related reactions","Type 1 diabetes, adrenal or pituitary insufficiency","Myocarditis (rare)","Serious or fatal immune events needing steroids and interruption"],"pain":"Minimal; only mild discomfort from IV cannulation. Side effects such as joint or muscle pain may occur in some patients.","preparation":["Confirmed cancer and approved indication; biomarker testing if relevant","Baseline blood tests: liver, kidney, thyroid, glucose","Baseline imaging for staging","Review of autoimmune history, transplant history and current medications","Pregnancy test and contraception counseling where relevant","Discussion of side effects and when to report symptoms urgently","Hepatitis B/C and HIV screening; exclude active tuberculosis","Baseline ECOG performance status assessment","Adequate venous access for intravenous infusion"],"recovery_timeline":[{"phase":"Infusion day","description":"About 30-minute IV infusion with brief observation; most patients go home the same day.","restrictions":[]},{"phase":"First days after each infusion","description":"Possible mild fatigue, rash or flu-like symptoms. Promptly report cough, breathlessness, severe diarrhea or rash, jaundice or weakness.","restrictions":[]},{"phase":"Ongoing treatment","description":"Cycles every 3 or 6 weeks with monitoring for delayed immune-related side effects, which can appear months into treatment or after it ends.","restrictions":["Do not self-treat immune-related symptoms; contact the oncology team"]}],"rehabilitation_days":{"min":0,"max":2,"unit":"days","qualifier":"Outpatient infusion with no surgical recovery; usual activities resume within 0-2 days, depending on fatigue and side effects."},"result_longevity":"In responders, benefit is often durable, lasting years and sometimes continuing after the course (up to about 2 years) ends. Duration depends on cancer type, stage and biomarkers.","revision_rate_pct":null,"scars":"No scarring is expected; at most there is a tiny, temporary mark at the IV cannulation site.","sessions_or_stages":{"sessions":{"min":1,"max":35,"unit":"visits","qualifier":"Infusions every 3 or 6 weeks for up to about 2 years (35 three-weekly cycles) or until progression."},"stages":[{"code":"infusion_cycles","label":"Repeated intravenous pembrolizumab infusions every 3 or 6 weeks","after":{"min":0,"max":730,"unit":"days","qualifier":"Spans the whole course from the first infusion."}}],"qualifier":"Number of cycles depends on cancer type, regimen, response and tolerance."},"success":{"metric":"Overall survival at 5 years (advanced NSCLC, PD-L1 ≥50%)","value":31.9,"unit":"percent","horizon":"5 years","population":"Adults with untreated advanced NSCLC, PD-L1 ≥50%, on pembrolizumab monotherapy","evidence_status":"limited"},"techniques":[{"name":"Pembrolizumab monotherapy","suits_whom":"Patients with suitable biomarkers (e.g., high PD-L1, MSI-high) or melanoma","recovery":"Outpatient infusion; no downtime in most patients."},{"name":"Pembrolizumab combined with chemotherapy","suits_whom":"Patients such as those with non-small cell lung cancer or other tumors where the combination is approved","recovery":"Added chemotherapy side effects can increase fatigue and recovery time after each cycle."}],"treatment_conditions":["outpatient"],"treatment_duration_hours":{"min":0.5,"max":1,"unit":"hours","qualifier":"Dose (200 mg every 3 weeks or 400 mg every 6 weeks) infused over 30 minutes, plus brief observation."},"initial_assessment_documents":["Pathology report with histology","PD-L1, MSI or dMMR test results","Staging CT or PET-CT reports","Prior treatment and surgery summary","Recent blood tests with liver and thyroid function","Oncologist letter on autoimmune disease or ECOG status"],"travel_trips":{"min":2,"max":35,"one_trip_possible":false,"qualifier":"Each 3- or 6-weekly infusion needs a visit; stay 1-3 days per trip. Fewer if a local oncologist continues."},"clinic_checks":{"status":"ok","items":[{"id":"C1","text":"Check that the medical team treating you has suitable qualifications","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you checked the qualifications of the medical team treating you?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C2","text":"Check that you can ask the treating team questions about your treatment","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Have you been able to ask them questions about your treatment?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C3","text":"Check that you are satisfied with the facilities and standards where you will be treated","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Are you satisfied with the facilities and standards at the clinic or hospital where you'll be treated?","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C4","text":"Check how your aftercare will be coordinated once treatment is over","scope":"treatment_abroad","source":{"url":"https://www.nhs.uk/using-the-nhs/healthcare-abroad/going-abroad-for-treatment/treatment-abroad-checklist/","host":"nhs.uk","quote":"Ensure you're clear about how your aftercare will be coordinated.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"C5","text":"Check whether follow-up care takes place at the same facility as the procedure","scope":"treatment_abroad","source":{"url":"https://www.cdc.gov/yellow-book/hcp/health-care-abroad/medical-tourism.html","host":"cdc.gov","quote":"Medical tourists should also know whether follow-up care is scheduled to occur at the same facility as the procedure.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":403}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"red_flags":{"status":"ok","items":[{"id":"F1","text":"The clinic or hospital refuses to discuss the details of the treatment when asked","scope":"treatment_abroad","source":{"url":"https://www.rcseng.ac.uk/patient-care/cosmetic-surgery/having-surgery-abroad","host":"rcseng.ac.uk","quote":"Be wary of surgeons and hospitals that do not want to discuss the details of surgery with you.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"F2","text":"An advert or information that guarantees complete success should raise concerns","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Any advert or information that guarantees complete success should raise concerns.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"F3","text":"Forceful persuasion or cheap, time-limited offers pushing you into a quick decision","scope":"treatment_abroad","source":{"url":"https://travelaware.campaign.gov.uk/surgery-abroad-cut-out-the-risk/","host":"travelaware.campaign.gov.uk","quote":"Don’t be pressured into quick decisions either through forceful persuasion or cheap, time limited offers.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"warning_signs":{"status":"ok","items":[{"id":"W1","text":"Fevers or flu-like symptoms with a rash","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Contact your care team right away if you notice fevers or flu-like symptoms with a rash.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W2","text":"Allergic reaction to the medicine","urgency":"contact_clinic","general":false,"source":{"url":"https://www.healthline.com/health/drugs/keytruda","host":"healthline.com","quote":"Call your doctor right away if you have an allergic reaction to Keytruda.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W3","text":"Any change in eyesight","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Tell your care team right away if you have any change in your eyesight.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W4","text":"Shortness of breath or trouble breathing","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Dry cough, shortness of breath or trouble breathing.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"W5","text":"Chest pain or fast or irregular heartbeat","urgency":"contact_clinic","general":false,"source":{"url":"https://my.clevelandclinic.org/health/drugs/20941-pembrolizumab-injection","host":"my.clevelandclinic.org","quote":"Heart muscle inflammation—unusual weakness or fatigue, shortness of breath, chest pain, fast or irregular heartbeat.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"take_home":{"status":"ok","items":[{"id":"T1","text":"Gives your home doctor information about your treatment and future care needs","document":"discharge letter for gp","source":{"url":"https://www.nhs.uk/using-the-nhs/nhs-services/hospitals/being-discharged-from-hospital/","host":"nhs.uk","quote":"You'll also be given a letter for your GP, providing information about your treatment and future care needs.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},{"id":"T2","text":"Ask for copies of all prescriptions before you leave","document":"prescription copies","source":{"url":"https://travelhealthpro.org.uk/news/699/travelling-abroad-for-treatment","host":"travelhealthpro.org.uk","quote":"Remember to ask for copies of all your treatment records, including prescriptions, scans and x-rays before you leave.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T3","text":"Home doctor needs the dates for required blood tests and follow-up appointments","document":"written aftercare plan","source":{"url":"https://sbuhb.nhs.wales/about-us/individual-patient-commissioning/ipc-folder/advice-on-accessing-treatment-abroad","host":"sbuhb.nhs.wales","quote":"This should include any medication and doses, as well as any dates that blood tests and follow-up appointments must be carried out.","tier":"tier1_medical","fetched_at":"2026-11-11","http_status":200}},{"id":"T4","text":"Tells any doctor the patient is on immunotherapy, so side effects are managed correctly","document":"immunotherapy wallet card","source":{"url":"https://www.ons.org/toolkits/immunotherapy-patient-wallet-card-1","host":"ons.org","quote":"The ONS Immunotherapy Patient Wallet Card is intended to communicate with healthcare providers who are not involved with a patient's cancer treatment.","tier":"tier1_medical","fetched_at":"2026-11-13","http_status":200}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your advanced lung cancer has spread to other body parts","name":"Targeted medicines for lung cancer","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment","host":"nhs.uk","quote":"Targeted medicines or immunotherapy are sometimes used to treat advanced lung cancer that has spread to other parts of the body.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"technique_details":{"status":"ok","items":[{"id":"pembrolizumab-monotherapy","name":"Pembrolizumab monotherapy","how_it_works":{"text":"The antibody blocks immune-inhibiting signals, allowing an anti-tumor immune response","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=pembro","host":"nctr-crs.fda.gov","quote":"Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}},{"id":"pembrolizumab-combined","name":"Pembrolizumab combined with chemotherapy","how_it_works":{"text":"The antibody is administered with another cancer treatment to treat cancer","source":{"url":"https://api.fda.gov/drug/label.json?search=openfda.application_number:%22BLA761467%22&limit=1","host":"api.fda.gov","quote":"The most common adverse reactions (≥20%) in patients receiving intravenous pembrolizumab and axitinib were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"}}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"preop_tests":{"status":"ok","items":[{"id":"T1","name":"Blood tests","aliases":["Blood tests","Baseline blood tests","Recent blood tests"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T2","name":"Liver function test","aliases":["Liver function test","liver","liver function","LFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T3","name":"Kidney function test","aliases":["Kidney function test","kidney","kidney function","renal function"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T4","name":"Thyroid function test","aliases":["Thyroid function test","thyroid","thyroid function","TFT"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"},{"field":"initial_assessment_documents","text":"Recent blood tests with liver and thyroid function"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T5","name":"Blood glucose test","aliases":["Blood glucose test","glucose","blood glucose"],"kind":"lab","origin":[{"field":"preparation","text":"Baseline blood tests: liver, kidney, thyroid, glucose"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T6","name":"Pregnancy test","aliases":["Pregnancy test"],"kind":"lab","origin":[{"field":"preparation","text":"Pregnancy test and contraception counseling where relevant"}],"what_it_checks":{"text":"Checks whether pregnancy is present because treatment can cause fetal harm","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Based on its mechanism of action, KEYTRUDA can cause fetal harm when administered to a pregnant woman.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T7","name":"Hepatitis B test","aliases":["Hepatitis B test","Hepatitis B/C screening","hepatitis B screening","HBV","Hepatitis C test","hepatitis C screening","HCV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T8","name":"HIV test","aliases":["HIV test","HIV screening","HIV"],"kind":"lab","origin":[{"field":"preparation","text":"Hepatitis B/C and HIV screening; exclude active tuberculosis"}],"what_it_checks":{"status":"missing","reason":"no_official_source"},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null},{"id":"T9","name":"PD-L1 test","aliases":["PD-L1 test","PD-L1","PD-L1 test results"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Shows PD-L1 protein in tumor cells, guiding immunotherapy choice","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"A PD-L1 test uses a sample of cancerous tumor tissue to measure how much of a protein called programmed-death ligand 1 (PD-L1) is found on the cancer cells.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"type":"case","text":"If you have certain types of cancer","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"You may need a PD-L1 test if you've been diagnosed with certain types of cancer that commonly cause high PD-L1 levels.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"test_prep":{"text":"Preparation varies with how the tumor sample is collected","source":{"url":"https://medlineplus.gov/lab-tests/pdl1-immunotherapy-tests/","host":"medlineplus.gov","quote":"Preparations for your test depend on how your tissue sample will be taken.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}}},{"id":"T10","name":"MSI test","aliases":["MSI test","MSI","microsatellite instability"],"kind":"lab","origin":[{"field":"initial_assessment_documents","text":"PD-L1, MSI or dMMR test results"}],"what_it_checks":{"text":"Checks tumor MSI-high status, which decides if Keytruda can treat it","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=mab","host":"nctr-crs.fda.gov","quote":"Microsatellite Instability-High or Mismatch Repair Deficient Colorectal Cancer (CRC) for the treatment of patients with unresectable or metastatic MSI-H or dMMR colorectal cancer (CRC) as determined by an FDA-authorized test.","tier":"tier1_medical","fetched_at":"2026-11-16","http_status":200}},"when_needed":{"status":"missing","reason":"no_official_source"},"test_prep":null}],"checked_at":"2026-11-16","next_check_at":"2027-11-16","version":2},"prep_in_advance":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"visit_and_day":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"},"if_something_changes":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-16","next_check_at":"2027-02-14"}}},"techniques":[{"id":"pembrolizumab-monotherapy","name":"Pembrolizumab monotherapy","how_it_works":{"id":"H1","text":"The antibody blocks immune-inhibiting signals, allowing an anti-tumor immune response","source":{"url":"https://nctr-crs.fda.gov/fdalabel/services/spl/set-ids/9333c79b-d487-4538-a9f0-71b91a02b287/spl-doc?hl=pembro","host":"nctr-crs.fda.gov","quote":"Pembrolizumab is a monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients with suitable biomarkers (e.g., high PD-L1, MSI-high) or melanoma","price_from":4300,"recovery":"Outpatient infusion; no downtime in most patients."},{"id":"pembrolizumab-combined","name":"Pembrolizumab combined with chemotherapy","how_it_works":{"id":"H1","text":"The antibody is administered with another cancer treatment to treat cancer","source":{"url":"https://api.fda.gov/drug/label.json?search=openfda.application_number:%22BLA761467%22&limit=1","host":"api.fda.gov","quote":"The most common adverse reactions (≥20%) in patients receiving intravenous pembrolizumab and axitinib were diarrhea, fatigue/asthenia, hypertension, hypothyroidism, decreased appetite, hepatotoxicity, palmar-plantar erythrodysesthesia, nausea, stomatitis/mucosal inflammation, dysphonia, rash, cough, and constipation.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200}},"recovery_daily":{"status":"missing","reason":"no_official_source"},"suits_whom":"Patients such as those with non-small cell lung cancer or other tumors where the combination is approved","price_from":5300,"recovery":"Added chemotherapy side effects can increase fatigue and recovery time after each cycle."}],"alternatives":{"status":"ok","items":[{"id":"A1","text":"Your advanced lung cancer has spread to other body parts","name":"Targeted medicines for lung cancer","source":{"url":"https://www.nhs.uk/conditions/lung-cancer/treatment","host":"nhs.uk","quote":"Targeted medicines or immunotherapy are sometimes used to treat advanced lung cancer that has spread to other parts of the body.","tier":"tier1_medical","fetched_at":"2026-11-12","http_status":200},"operation_id":null}],"checked_at":"2026-11-12","next_check_at":"2027-11-12","version":1},"diagnostic":{"status":"not_applicable"},"country":{"why":{"status":"missing","reason":"no_official_source","checked_at":"2026-11-11","next_check_at":"2027-02-09"},"travel":{"status":"ok","items":[{"id":"V1","item":"visa","audience":"uk","volatile":true,"text":"UK passport holders can travel to Italy without a visa for up to 90 days in any 180-day period","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/entry-requirements","host":"gov.uk","quote":"You can travel without a visa to the Schengen area , which includes Italy, for up to 90 days in any 180-day period.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V2","item":"visa","audience":"us","volatile":true,"text":"U.S. citizens may enter Italy without a visa for up to 90 days for tourist or business purposes","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"U.S. citizens may enter Italy for up to 90 days for tourist or business purposes without a visa.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V3","item":"passport_validity","audience":"uk","volatile":true,"text":"A UK passport must expire at least 3 months after the day you plan to leave the Schengen area","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/entry-requirements","host":"gov.uk","quote":"have an ‘expiry date’ at least 3 months after the day you plan to leave the Schengen area (the expiry date does not need to be within 10 years of the date of issue)","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V4","item":"passport_validity","audience":"us","volatile":true,"text":"A U.S. passport must be valid for at least 3 months beyond the period of stay in Italy","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"Your passport must be valid for at least 3 months beyond the period of stay.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V5","item":"medicines","audience":"all","volatile":false,"text":"Foreigners may bring personal medications for 30 days into Italy; bringing a copy of the prescription is recommended","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"According to the Ministry of Health, foreigners entering Italy are allowed to bring personal medications for a period of 30 days, but it is recommended that travelers also bring a copy of their prescription with them.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V6","item":"ghic","audience":"uk","volatile":false,"text":"A UK GHIC or EHIC is needed to get medically necessary state healthcare in Italy","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/health","host":"gov.uk","quote":"To get medically necessary state healthcare in Italy, you need a Global Health Insurance Card ( GHIC ) or a European Health Insurance Card ( EHIC ).","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}},{"id":"V7","item":"hospital_payment","audience":"all","volatile":false,"text":"Private hospitals in Italy usually require advance payment or proof of adequate insurance before admitting a patient","source":{"url":"https://travel.state.gov/content/travel/en/international-travel/International-Travel-Country-Information-Pages/Italy.html","host":"travel.state.gov","quote":"Private hospitals usually require advance payment or proof of adequate insurance before admitting a patient.","tier":"official_travel","fetched_at":"2026-11-11","http_status":403}},{"id":"V8","item":"emergency_number","audience":"all","volatile":false,"text":"Dial 118 and ask for an ambulance in Italy","source":{"url":"https://www.gov.uk/foreign-travel-advice/italy/health","host":"gov.uk","quote":"Dial 118 and ask for an ambulance.","tier":"official_travel","fetched_at":"2026-11-11","http_status":200}}],"checked_at":"2026-11-11","next_check_at":"2026-12-11","version":1},"other_countries_with_page":["azerbaijan","china","dominican-republic","egypt","germany","india","israel","japan","malaysia","mexico","morocco","republic-of-korea","spain","switzerland","thailand","turkey","ukraine","united-states"]},"often_combined_with":{"status":"missing","reason":"not_collected"},"reviews":{"avg_rating":4.6,"count":71,"scope":"clinic","rating_scale":5,"pros":{"status":"missing","reason":"not_collected"},"cons":{"status":"missing","reason":"not_collected"}},"current":{"seo_text":"<p class=\"bm-h1-lead\">Immunotherapy with keytruda in Italy is offered by San Raffaele in Milan. The clinic is rated 4.6/5 in 71 verified patient reviews on Bookimed.</p>","faq":[{"q":"Is Keytruda reimbursed by the Italian National Health Service (SSN)?","a":"<p>The Italian National Health Service (SSN) reimburses Keytruda (pembrolizumab) for specific oncological indications approved by the Italian Medicines Agency (AIFA). Categorized as Class H, the drug is fully covered when administered within hospital settings for conditions like melanoma, lung cancer, and cervical cancer.</p> <ul> <li><strong>Regulatory oversight:</strong> AIFA manages reimbursement through mandatory monitoring registers to track patient safety.</li> <li><strong>Reimbursed indications:</strong> Coverage includes advanced non-small cell lung cancer and stage III melanoma.</li> <li><strong>Clinical requirements:</strong> Patients must meet indication-specific criteria and register in official monitoring databases.</li> <li><strong>Recent expansions:</strong> Reimbursement now includes first-line treatment for advanced or metastatic PD-L1+ cervical cancer.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> While technically a national system, Bookimed data shows regional variations in approval speeds. Centers in Milan, such as San Raffaele, often navigate these protocols efficiently due to their IRCCS accreditation. This status combines clinical care with advanced research, streamlining the administrative process for immunotherapy.</p> <p><strong>Patient Consensus:</strong> Patients emphasize starting paperwork early as authorization can take several weeks. If the initial request is denied, many report successful reimbursement after appealing with more clinical data.</p>"},{"q":"What cancers is Keytruda approved for in Italy?","a":"<p>Keytruda (pembrolizumab) is approved in Italy for diverse malignancies following European Medicines Agency (EMA) centralized authorizations. The Italian Medicines Agency (AIFA) regulates national reimbursement for advanced melanoma, non-small cell lung cancer, renal cell carcinoma, and various gastrointestinal, gynecologic, and hematologic cancers.</p> <ul> <li><strong>Respiratory cancers:</strong> Covers advanced non-small cell lung cancer and malignant pleural mesothelioma.</li> <li><strong>Gastrointestinal indications:</strong> Approved for esophageal, gastric, biliary tract, and MSI-H colorectal cancers.</li> <li><strong>Genitourinary types:</strong> Used for renal cell carcinoma and urothelial carcinoma treatments.</li> <li><strong>Gynecologic cancers:</strong> Authorization includes endometrial, cervical, and specific ovarian or fallopian cancers.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian research centers like San Raffaele in Milan integrate Keytruda into advanced research-driven protocols. While AIFA manages reimbursement, Northern Italian facilities often provide faster diagnostic processing for PD-L1 testing. This logistical speed can significantly accelerate the start of immunotherapy compared to other regions.</p> <p><strong>Patient Consensus:</strong> Patients report that melanoma and lung cancer indications move the fastest through the public system. Early PD-L1 testing is essential to avoid common multi-week delays in starting treatment.</p>"},{"q":"What are the common and serious side effects of Keytruda?","a":"<p>Common side effects of Keytruda (pembrolizumab) include fatigue, skin rashes, and digestive issues. While usually manageable, serious risks involve immune-mediated inflammation where the body attacks healthy organs. Italian research centers like San Raffaele monitor patients closely for pneumonitis, colitis, and thyroid dysfunction during treatment.</p> <ul> <li><strong>Common symptoms:</strong> Fatigue affects 28% of patients, alongside nausea, cough, and musculoskeletal pain.</li> <li><strong>Organ inflammation:</strong> Immune-mediated reactions can cause lung, liver, kidney, or colon inflammation.</li> <li><strong>Hormonal changes:</strong> Keytruda may damage the thyroid, adrenal, or pituitary glands during therapy.</li> <li><strong>Serious skin reactions:</strong> Rare conditions like Stevens-Johnson syndrome require immediate medical attention and intervention.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian IRCCS-accredited hospitals like San Raffaele combine treatment with high-level research. This dual approach helps clinicians catch rare immune-mediated side effects early. Patients benefit from specialized multidisciplinary teams that manage complex endocrine or neurological reactions during long-term immunotherapy cycles.</p>"},{"q":"How is Keytruda administered and what new option is available?","a":"<p>Keytruda is traditionally administered via a 30-minute intravenous infusion into a vein every 3 or 6 weeks. A new subcutaneous injection now allows administration in only 2 to 5 minutes. This version delivers the medication just under the skin of the thigh or abdomen.</p> <ul> <li><strong>Intravenous infusion:</strong> Administered every 3 weeks (200 mg) or 6 weeks (400 mg).</li> <li><strong>Subcutaneous injection:</strong> This new option reduces clinic chair time by nearly 50%.</li> <li><strong>Treatment frequency:</strong> Dosing intervals remain consistent at 3 or 6 weeks.</li> <li><strong>Mechanism:</strong> Added enzymes help the body absorb the subcutaneous medicine quickly.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian research centers like San Raffaele often lead in adopting these faster delivery methods. While the subcutaneous option saves time, regional public health availability across Italy fluctuates. Choosing private oncology care in Milan may ensure immediate access to 5-minute injection sessions.</p> <p><strong>Patient Consensus:</strong> Patients report that subcutaneous injections significantly improve comfort by preventing vein fatigue. Many recommend tracking thyroid levels early as immune side effects remain identical between both methods.</p>"},{"q":"How do patients access Keytruda treatment in Italy?","a":"<p>Patients access Keytruda in Italy through the Servizio Sanitario Nazionale (SSN) or private oncology centers. The Italian Medicines Agency (AIFA) regulates eligibility based on clinical indications. Access requires an oncologist prescription, biomarker testing like PD-L1 expression, and administration at certified hospitals or research institutes.</p> <ul> <li><strong>System regulation:</strong> AIFA manages pricing and national reimbursement protocols.</li> <li><strong>Access barriers:</strong> Biomarker testing for PD-L1 is mandatory for most indications.</li> <li><strong>Facility types:</strong> Delivery occurs in specialized IRCCS research hospitals like San Raffaele.</li> <li><strong>Regional variation:</strong> Approval speeds vary between northern and southern Italian health authorities.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian research hospitals like San Raffaele combine clinical care with extensive research activity. This dual status often grants patients access to newer immunotherapy protocols earlier than standard clinics. Focus on centers with IRCCS accreditation to ensure the most current oncology standards.</p> <p><strong>Patient Consensus:</strong> Patients report that private clinics provide much faster access, usually within 2 to 4 weeks. Most emphasize bringing complete genetic and imaging reports to the first visit to prevent significant delays.</p>"},{"q":"What is the typical response rate observed with Keytruda?","a":"<p>Keytruda (pembrolizumab) shows a wide range of response rates, generally averaging 33.8% across various cancers. Effectiveness depends heavily on PD-L1 expression and genetic indicators like MSI-H. Reported outcomes vary from 11% in gastric cancer to over 80% in specific Hodgkin lymphoma cases.</p> <ul> <li><strong>Hodgkin lymphoma:</strong> Clinical data shows high objective response rates ranging from 73% to 83%.</li> <li><strong>Advanced melanoma:</strong> Response rates typically vary between 21% and 34% for refractory cases.</li> <li><strong>Lung cancer:</strong> Monotherapy for high PD-L1 patients achieves approximately 44.8% response rates.</li> <li><strong>Genetic markers:</strong> Tumors with high microsatellite instability (MSI-H) average roughly 39.6% response.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Italian research centers like San Raffaele in Milan manage massive volumes, serving 300,000 patients annually. This scale is vital for immunotherapy because high-volume centers often possess more granular data on PD-L1 testing. Choosing these experienced hubs ensures more accurate response predictions based on your specific biomarker profile.</p> <p><strong>Patient Consensus:</strong> Many patients emphasize that initial scans at 8–12 weeks might show no change. They suggest viewing stable disease as a significant clinical victory even without a full response.</p>"},{"q":"Are there accelerated access routes for Keytruda in Italy?","a":"<p>Italy offers several accelerated access routes for Keytruda, primarily through the Italian Medicines Agency (AIFA) framework. Patients access these therapies via the Law 648/96 list, compassionate use programs, or the AIFA National Fund. These pathways ensure treatment for patients with urgent medical needs before full national reimbursement.</p> <ul> <li><strong>Law 648/96 list:</strong> Provides early reimbursement for medicines with significant unmet clinical needs.</li> <li><strong>Compassionate use:</strong> Allows pharmaceutical companies to provide treatments like Pembolizumab free of charge.</li> <li><strong>AIFA 5% fund:</strong> Finances individual requests for innovative drugs in serious disease cases.</li> <li><strong>Class C-nn status:</strong> Permits local hospitals to purchase EMA-authorized drugs using regional funds.</li> </ul> <p><strong>Bookimed Expert Insight:</strong> Northern Italian medical centers like San Raffaele often process early access requests faster due to local regional funding. The IRCCS accreditation at these research hospitals combines clinical care with active immunotherapy trials. Patients should target these research-heavy facilities first to increase their chances of securing early access status.</p> <p><strong>Patient Consensus:</strong> Many patients recommend bringing printed AIFA guidelines to initial consultations to clarify eligibility for compassionate use. Local support groups suggest budgeting for one private dose while waiting for regional reimbursement paperwork processing.</p>"}],"h2":[{"text":"How Much Does Immunotherapy with Keytruda (Pembolizumab) Cost in Italy?","kind":"content"},{"text":"Your Benefits and Guarantees with Bookimed","kind":"content"},{"text":"Your personal Bookimed medical coordinator","kind":"content"},{"text":"Discover the Best Immunotherapy with Keytruda (Pembolizumab) Clinics in Italy: 1 Verified Option and Prices","kind":"content"},{"text":"Immunotherapy with Keytruda (Pembolizumab) Overview in Italy","kind":"content"},{"text":"Video Stories from Bookimed Patients","kind":"ui"},{"text":"Reviews about Bookimed: Discover Patients' Insights","kind":"ui"},{"text":"Share this content","kind":"ui"},{"text":"Fast Facts about Immunotherapy with Keytruda (Pembolizumab)","kind":"content"},{"text":"FAQ about Immunotherapy with Keytruda (Pembolizumab) in Italy","kind":"content"},{"text":"Get a free consultation","kind":"ui"}]},"placeholders":{"price_from":"{{price_from}}","clinics_count":"{{clinics_count}}","cities_count":"{{cities_count}}","savings_pct":"{{savings_pct}}","data_date":"{{data_date}}"},"legal":{"restricted_markets":{"status":"missing","reason":"not_collected"}},"conflicts":[]}